CY1119595T1 - Χορηγουμενες απο το στομα συνθεσεις καθυστερημενης αποδεσμευσης που περιεχουν αμορφο cddo-me - Google Patents
Χορηγουμενες απο το στομα συνθεσεις καθυστερημενης αποδεσμευσης που περιεχουν αμορφο cddo-meInfo
- Publication number
- CY1119595T1 CY1119595T1 CY20171101183T CY171101183T CY1119595T1 CY 1119595 T1 CY1119595 T1 CY 1119595T1 CY 20171101183 T CY20171101183 T CY 20171101183T CY 171101183 T CY171101183 T CY 171101183T CY 1119595 T1 CY1119595 T1 CY 1119595T1
- Authority
- CY
- Cyprus
- Prior art keywords
- amporate
- cddo
- sponsored
- oral
- compositions containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Φαρμακευτικές μορφοποιήσεις που παρουσιάζουν ένα επιθυμητά χαμηλό Cmax, ανάμεσα σε άλλες ιδιότητες, και περιέχουν σωματίδια άμορφης μεθυλικής βαρδοξολόνης, είτε σε καθαρή μορφή είτε στη μορφή ενός στερεού αιωρήματος, προσμεμειγμένα με σωματίδια μιας υδρόφιλης συνδετικής ουσίας. Τέτοιες μορφοποιήσεις κατέχουν το πλεονέκτημα της υψηλότερης βιοδιαθεσιμότητας χορήγησης από το στόμα, σε σχέση με μορφοποιήσεις που βασίζονται στην κρυσταλλική μορφή της μεθυλικής βαρδοξολόνης.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15260809P | 2009-02-13 | 2009-02-13 | |
| PCT/US2010/024127 WO2010093944A2 (en) | 2009-02-13 | 2010-02-12 | Delayed release, oral dosage compositions that contain amorphous cddo-me |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119595T1 true CY1119595T1 (el) | 2018-03-07 |
Family
ID=42335073
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171101183T CY1119595T1 (el) | 2009-02-13 | 2017-11-13 | Χορηγουμενες απο το στομα συνθεσεις καθυστερημενης αποδεσμευσης που περιεχουν αμορφο cddo-me |
| CY20191100761T CY1122066T1 (el) | 2009-02-13 | 2019-07-17 | Χορηγουμενες απο το στομα συνθεσεις καθυστερημενης εκλυσης που περιεχουν αμορφο cddo-me |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100761T CY1122066T1 (el) | 2009-02-13 | 2019-07-17 | Χορηγουμενες απο το στομα συνθεσεις καθυστερημενης εκλυσης που περιεχουν αμορφο cddo-me |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US8747901B2 (el) |
| EP (2) | EP3254675B1 (el) |
| JP (1) | JP5775464B2 (el) |
| KR (2) | KR20140016441A (el) |
| CN (2) | CN105232471A (el) |
| AU (1) | AU2010213594B2 (el) |
| BR (1) | BRPI1008023B8 (el) |
| CA (1) | CA2752048C (el) |
| CO (1) | CO6361904A2 (el) |
| CY (2) | CY1119595T1 (el) |
| DK (2) | DK3254675T3 (el) |
| EA (1) | EA023652B1 (el) |
| ES (2) | ES2646816T3 (el) |
| HK (1) | HK1220130A1 (el) |
| HR (2) | HRP20171639T1 (el) |
| HU (2) | HUE044005T2 (el) |
| IL (1) | IL214258A (el) |
| LT (2) | LT2395979T (el) |
| MX (1) | MX2011008344A (el) |
| MY (1) | MY173715A (el) |
| NO (1) | NO2395979T3 (el) |
| NZ (1) | NZ594488A (el) |
| PL (2) | PL2395979T3 (el) |
| PT (2) | PT3254675T (el) |
| SG (1) | SG173601A1 (el) |
| SI (2) | SI3254675T1 (el) |
| TR (1) | TR201909743T4 (el) |
| WO (1) | WO2010093944A2 (el) |
| ZA (1) | ZA201105630B (el) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| TWI492745B (zh) | 2008-01-11 | 2015-07-21 | Reata Pharmaceuticals Inc | 合成的三萜系化合物及其使用於治療疾病之方法 |
| HUE041221T2 (hu) | 2008-04-18 | 2019-05-28 | Reata Pharmaceuticals Inc | Antioxidáns gyulladás modulátorok: a C-17 atomon amino- és más módosításokkal rendelkezõ oleanolsav-származékok |
| JP5529850B2 (ja) | 2008-04-18 | 2014-06-25 | リアタ ファーマシューティカルズ インコーポレイテッド | 抗酸化炎症モジュレーター：ｃ環中に飽和を有するオレアノール酸誘導体 |
| US8258329B2 (en) | 2008-04-18 | 2012-09-04 | Reata Pharmaceuticals, Inc. | Dehydroandrosterone analogs including an anti-inflammatory pharmacore and methods of use |
| TWI584808B (zh) | 2008-04-18 | 2017-06-01 | 瑞塔醫藥有限責任公司 | 抗氧化發炎調節劑：ｃ－１７同系齊墩果酸衍生物 |
| US8314137B2 (en) | 2008-07-22 | 2012-11-20 | Trustess Of Dartmouth College | Monocyclic cyanoenones and methods of use thereof |
| TR201909743T4 (tr) | 2009-02-13 | 2019-07-22 | Reata Pharmaceuticals Inc | Amorf CDDO-ME içeren gecikmeli salımlı oral dozaj bileşimleri. |
| EP2558105B1 (en) | 2010-04-12 | 2019-11-20 | Reata Pharmaceuticals, Inc. | Bardoxolone methyl for the treatment of obesity |
| KR102000301B1 (ko) | 2010-12-17 | 2019-07-15 | 리아타 파마슈티컬즈, 아이엔씨. | 산화방지성 염증 조절제로서의 피라졸릴 및 피리미디닐 트리사이클릭 엔온 |
| RS59200B1 (sr) | 2011-03-11 | 2019-10-31 | Reata Pharmaceuticals Inc | Derivati c4-monometil triterpenoida i postupci za njihovu upotrebu |
| CN103156861B (zh) * | 2011-12-08 | 2015-11-25 | 陈丽梅 | 齐敦果酸衍生物及其可药用盐在治疗糖尿病眼病中的应用 |
| US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| EA030468B1 (ru) | 2012-04-27 | 2018-08-31 | Рита Фармасьютикалз, Инк. | 2,2-дифторпропионамидные производные бардоксолон-метила, их полиморфные формы и способы применения |
| US8981144B2 (en) | 2012-05-08 | 2015-03-17 | Trustees Of Dartmouth College | Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof |
| US8921419B2 (en) | 2012-05-08 | 2014-12-30 | Trustees Of Dartmouth College | Triterpenoids and compositions containing the same |
| US9556222B2 (en) | 2012-06-15 | 2017-01-31 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
| CN104955833B (zh) | 2012-09-10 | 2019-10-11 | 里亚塔医药公司 | 齐墩果酸的c17-烷二基与烯二基衍生物及其使用方法 |
| US9278912B2 (en) | 2012-09-10 | 2016-03-08 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| TWI649330B (zh) | 2013-04-24 | 2019-02-01 | 艾伯維有限公司 | 甲基巴多索龍之２，２－二氟丙醯胺衍生物、其多晶形及其使用方法 |
| CN105517554B (zh) | 2013-08-23 | 2021-01-15 | 里亚塔医药公司 | 使用甲基巴多索隆或其类似物治疗和预防内皮功能障碍的方法 |
| US20170333450A1 (en) | 2014-10-31 | 2017-11-23 | The Regents Of The University Of California | Compositions and methods for treating hiv-associated cognitive dysfunction |
| NZ734292A (en) | 2015-02-12 | 2022-09-30 | Reata Pharmaceuticals Inc | Imidazolyl tricyclic enones as antioxidant inflammation modulators |
| US11584775B2 (en) | 2015-09-23 | 2023-02-21 | Reata Pharmaceuticals, Inc. | C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses |
| KR102486434B1 (ko) | 2016-11-08 | 2023-01-09 | 리아타 파마슈티컬즈 홀딩스, 엘엘씨 | 바독솔론 메틸 또는 이의 유사체를 사용하는 알포트 증후군의 치료 방법 |
| TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| US11427533B2 (en) | 2017-07-13 | 2022-08-30 | Pliva Hrvatska D.O.O. | Crystalline polymorphs of bardoxolone methyl |
| JP7244536B2 (ja) | 2018-04-06 | 2023-03-22 | キャプシュゲル・ベルジウム・エヌ・ヴィ | メタクリル酸メチル－メタクリル酸コポリマーからなる低アスペクト比の粒子のための噴霧乾燥方法 |
| BR112020025605A2 (pt) | 2018-06-15 | 2021-03-23 | Reata Pharmaceuticals, Inc. | compostos de pirazol e imidazol para inibição de il-17 e rorgama |
| CN113164436A (zh) | 2018-11-27 | 2021-07-23 | 协和麒麟株式会社 | 药物组合物 |
| MX2022014034A (es) | 2020-05-09 | 2023-01-11 | Reata Pharmaceuticals Holdings Llc | Métodos para tratar covid-19 con el uso de bardoxolona metilo o análogos de esta. |
| AU2021397631A1 (en) | 2020-12-11 | 2023-07-20 | Reata Pharmaceuticals Holdings, LLC | Synthetic triterpenoids for use in therapy |
| CN114558019A (zh) * | 2022-03-26 | 2022-05-31 | 中国科学院昆明动物研究所 | 一种Rab13基因抑制剂及应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| US7435755B2 (en) * | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
| JP2008110962A (ja) | 2006-08-02 | 2008-05-15 | Santen Pharmaceut Co Ltd | Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤 |
| JP4315182B2 (ja) * | 2006-10-30 | 2009-08-19 | ミツミ電機株式会社 | カメラモジュール |
| JP2008247898A (ja) * | 2007-03-08 | 2008-10-16 | Santen Pharmaceut Co Ltd | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
| US8088824B2 (en) * | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
| TWI492745B (zh) | 2008-01-11 | 2015-07-21 | Reata Pharmaceuticals Inc | 合成的三萜系化合物及其使用於治療疾病之方法 |
| TR201909743T4 (tr) | 2009-02-13 | 2019-07-22 | Reata Pharmaceuticals Inc | Amorf CDDO-ME içeren gecikmeli salımlı oral dozaj bileşimleri. |
-
2010
- 2010-02-12 TR TR2019/09743T patent/TR201909743T4/tr unknown
- 2010-02-12 EP EP17181174.8A patent/EP3254675B1/en active Active
- 2010-02-12 ES ES10704298.8T patent/ES2646816T3/es active Active
- 2010-02-12 PT PT17181174T patent/PT3254675T/pt unknown
- 2010-02-12 KR KR1020147001850A patent/KR20140016441A/ko not_active Application Discontinuation
- 2010-02-12 SG SG2011057122A patent/SG173601A1/en unknown
- 2010-02-12 SI SI201031906T patent/SI3254675T1/sl unknown
- 2010-02-12 NO NO10704298A patent/NO2395979T3/no unknown
- 2010-02-12 SI SI201031570T patent/SI2395979T1/sl unknown
- 2010-02-12 ES ES17181174T patent/ES2731601T3/es active Active
- 2010-02-12 AU AU2010213594A patent/AU2010213594B2/en active Active
- 2010-02-12 HU HUE17181174A patent/HUE044005T2/hu unknown
- 2010-02-12 CN CN201510540397.8A patent/CN105232471A/zh active Pending
- 2010-02-12 PT PT107042988T patent/PT2395979T/pt unknown
- 2010-02-12 US US13/201,398 patent/US8747901B2/en active Active
- 2010-02-12 DK DK17181174.8T patent/DK3254675T3/da active
- 2010-02-12 MY MYPI2011003694A patent/MY173715A/en unknown
- 2010-02-12 PL PL10704298T patent/PL2395979T3/pl unknown
- 2010-02-12 WO PCT/US2010/024127 patent/WO2010093944A2/en active Application Filing
- 2010-02-12 CN CN201080007105XA patent/CN102387789A/zh active Pending
- 2010-02-12 KR KR1020117021250A patent/KR101483203B1/ko active IP Right Grant
- 2010-02-12 MX MX2011008344A patent/MX2011008344A/es active IP Right Grant
- 2010-02-12 BR BRPI1008023A patent/BRPI1008023B8/pt active IP Right Grant
- 2010-02-12 LT LTEP10704298.8T patent/LT2395979T/lt unknown
- 2010-02-12 EP EP10704298.8A patent/EP2395979B1/en active Active
- 2010-02-12 NZ NZ594488A patent/NZ594488A/xx unknown
- 2010-02-12 EA EA201190092A patent/EA023652B1/ru not_active IP Right Cessation
- 2010-02-12 JP JP2011550279A patent/JP5775464B2/ja active Active
- 2010-02-12 LT LTEP17181174.8T patent/LT3254675T/lt unknown
- 2010-02-12 HU HUE10704298A patent/HUE035013T2/en unknown
- 2010-02-12 CA CA2752048A patent/CA2752048C/en active Active
- 2010-02-12 PL PL17181174T patent/PL3254675T3/pl unknown
- 2010-02-12 DK DK10704298.8T patent/DK2395979T3/da active
-
2011
- 2011-07-24 IL IL214258A patent/IL214258A/en active IP Right Grant
- 2011-07-29 ZA ZA2011/05630A patent/ZA201105630B/en unknown
- 2011-08-09 CO CO11100847A patent/CO6361904A2/es not_active Application Discontinuation
-
2014
- 2014-04-30 US US14/266,031 patent/US9155721B2/en active Active
-
2016
- 2016-07-13 HK HK16108241.2A patent/HK1220130A1/zh unknown
-
2017
- 2017-10-26 HR HRP20171639TT patent/HRP20171639T1/hr unknown
- 2017-11-13 CY CY20171101183T patent/CY1119595T1/el unknown
-
2019
- 2019-06-17 HR HRP20191092 patent/HRP20191092T1/hr unknown
- 2019-07-17 CY CY20191100761T patent/CY1122066T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119595T1 (el) | Χορηγουμενες απο το στομα συνθεσεις καθυστερημενης αποδεσμευσης που περιεχουν αμορφο cddo-me | |
| CY1117479T1 (el) | Βενζοδιαζεπινικος αναστολεας bromodomain | |
| CY1118496T1 (el) | Φαρμακεyτικες συνθεσεις | |
| CY1122853T1 (el) | Σταθερα σκευασματα λινακλοτιδης | |
| IL193074A0 (en) | Stable pharmaceutical formulations of montelukast sodium | |
| NO20080202L (no) | Nanopartikulaere clopidogrel og aspirin kombinasjonsformuleringer | |
| CY1113526T1 (el) | Τροποποιησεις του rνα, οι οποιες οδηγουν σε αυξημενη σταθεροτητα μεταγραφηματων και αποτελεσματικοτητα mεταφρασης | |
| IL204521A0 (en) | Oxadiazole derivatives, their preparation and pharmaceutical compositions containing them | |
| BRPI0813455A2 (pt) | Derivado de 17beta-ciano-18a-homo-19-nor-androst-4-eno, seu uso e medicamentos contendo este derivado. | |
| EP2569330A4 (en) | CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF | |
| CY1117237T1 (el) | Συνθεσεις σταθερων τιακουμυκινων | |
| WO2012075362A3 (en) | Chemokine cxcr4 receptor modulators and used related thereto | |
| CY1115938T1 (el) | Νεα συνθεση για αυξηση της bio-διαθεσιμοτητας της νεουρτουρινης (neurturin) | |
| ZA200804163B (en) | New adjuvants on the basis of bisacyloxypropylcysteine conjugates and derivatives and their uses in pharmaceutical compositions | |
| WO2012082483A3 (en) | Multifunctional linkers and methods for the use thereof | |
| WO2009039157A3 (en) | Orlistat pharmaceutical formulations | |
| CY1110213T1 (el) | Παραγωγα αζολοπυριδιν-2-ονης ως αναστολεις λιπασων και φωσφολιπασων | |
| CY1116266T1 (el) | Σταθερα αλατα της s-αδενοσυλμεθειονινης και μεθοδος παρασκευης τους | |
| MX2009012370A (es) | Formulacion de antraciclina de baja viscosidad. | |
| WO2011135580A3 (en) | Pharmaceutical compositions of sirolimus | |
| CY1119315T1 (el) | Στερεες μορφες που περιεχουν μελοξικαμη με βελτιωμενη στοματικη γευση και η διαδικασια για τηn προετοιμασια τους | |
| DK1608344T3 (da) | Orale cladribin-formuleringer | |
| NO20080034L (no) | Benzotiazol-2-on derivater som lipase og fosfolipaseinhibitorer | |
| RS52461B (en) | FLUPENTIKSOL COMPOSITIONS | |
| WO2012029074A3 (en) | Pharmaceutical compositions of linezolid |